Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated.
2 Growth Stocks with Explosive Upside and 1 We Brush Off Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
1 Reason Every Investor Should Know About Novo Nordisk (NVO) The company could be on the verge of turning the tide in the battle over weight loss drugs.
Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 trial, with positive trends in overall survival.
Ozempic Is The New Botox And Big Pharma Is Printing Billions Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.
Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (
NYSE:LLY ) and the best and worst performers in the branded pharmaceuticals industry.
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments.
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.
3 Stocks to Buy and Hold Forever These stocks are built for the long run.
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day? The company's innovative engine continues to function well.
2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts Consensus price targets set by experts who follow these businesses are way above their recent prices.
Down 34%, Should You Buy the Dip on Viking Therapeutics? Viking aims to enter the billion-dollar weight loss drug market.
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results.
ETF Traders Are Quietly Positioning For Market Turbulence: Direxion Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves.
The 6 Best Stocks to Buy Right Now in September (2025)! There is something for everyone in this list of excellent stocks to buy.
Where Will Eli Lilly Be in 3 Years? The weight-loss drug opportunity could approach $100 billion by the end of the decade.
The Problem With Weight Loss Stocks There are new ways to tackle weight loss, but the stocks leading the way are lagging.
After Copycat Boom, China's Drugmakers Target Global Generics Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.
Is Novo Nordisk Stock a Buy Now? A 57% risk reduction for heart attacks and strokes sounds like an amazing result.
